Inovio Pharmaceu Stock Price, News & Analysis

INOVIO (NASDAQ: INO) announced topline results from the Phase 3 REVEAL2 trial of VGX-3100 for cervical HSIL, where it did not meet the primary endpoint in a biomarker-selected group but showed statistical significance in the all-participants population. The company reported a fourth-quarter 2022 revenue of $125,000 against total operating expenses of $56.1 million, leading to a net loss of $54.5 million. Despite challenges, INOVIO ended 2022 with $253 million in cash, sufficient to fund operations into Q1 2025. Positive preliminary data were also presented for INO-3107 and INO-4201, suggesting potential in HPV and Ebola treatment domains.

INOVIO (NASDAQ: INO) announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial for INO-3107, aimed at treating HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP). Of 11 patients, 10 (91%) experienced a reduction in surgical interventions, with a statistically significant median decrease of three surgeries compared to the previous year. The treatment was well-tolerated, and results aligned with the first cohort. The trial's successful outcomes may pave the way for further regulatory engagement and potential advancements in DNA medicine therapies.

INOVIO (NASDAQ: INO) announced that it will release its fourth quarter and year-end 2022 financial results on March 1, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. The company is focused on developing DNA medicines for HPV-associated diseases and cancer, utilizing its proprietary CELLECTRA® device. Details for accessing the live event and archived presentation are available on their investor relations website.

INOVIO (NASDAQ: INO) announced the equity grant of stock options to a new employee under its 2022 Inducement Plan on February 2, 2023. The Board's Compensation Committee approved the award of options to purchase 15,625 shares at an exercise price of $1.79, reflecting the stock's closing price on the Grant Date. The options will vest over four years, contingent upon continued employment. INOVIO focuses on DNA medicines to treat HPV-associated diseases, cancer, and infectious diseases through its proprietary device, CELLECTRA®.

INOVIO (NASDAQ: INO) announced positive results from a Phase 1b clinical trial of INO-4201, a DNA vaccine candidate as a booster for individuals previously vaccinated with Ervebo. Conducted with 46 participants, the trial demonstrated that INO-4201 was well-tolerated and boosted humoral responses in 100% of treated subjects (36 of 36). Neutralizing titers were significantly higher in the INO-4201 group compared to placebo, with responses maintained even 24 weeks later. The trial was sponsored by Geneva University Hospitals and funded by DARPA. The results emphasize the potential of INO-4201 for future Ebola Virus Disease prevention.

INOVIO (NASDAQ: INO) announced a strategic reorganization aimed at enhancing operational efficiency and advancing its DNA medicine programs. Key elements include an 11% reduction in headcount, expected to yield annual savings of approximately $4.3 million, and a one-time restructuring charge of around $1.1 million anticipated in Q1 2023. The reorganization follows the discontinuation of certain clinical development programs in late 2022. INOVIO confirmed that data readouts for its product candidates, INO-3107 and VGX-3100, are projected for the first quarter of 2023, aligning with its focus on HPV-associated diseases.

INOVIO (NASDAQ: INO) has announced the discontinuation of its product candidates for Lassa Fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700) after initial study analyses by CEPI. Despite well-tolerated trials in Ghana and Jordan, the two-dose regimen did not meet the selection criteria for further development. INOVIO emphasizes its commitment to its DNA medicine candidates and future collaborations with CEPI. The company plans to publish data to support ongoing research.

INOVIO (NASDAQ: INO) announced positive interim Phase 1/2 data for INO-3107, a potential treatment for recurrent respiratory papillomatosis, indicating a median decrease of three surgical interventions in 76% of participants. The company reported Q3 2022 revenue of $9.2 million, significantly up from $292,000 in 2021, primarily due to a contract with the U.S. Department of Defense. INOVIO also updated its cash runway guidance, now extending into Q1 2025. However, net loss for the quarter was $37.8 million, an improvement from the previous year's $60.2 million.

INOVIO (NASDAQ:INO) has announced the discontinuation of internal funding for INO-4800, its COVID-19 heterologous booster vaccine, due to reduced global demand and changes in regulatory conditions. CEO Dr. Jacqueline Shea emphasized the need to reallocate resources towards other promising candidates such as INO-3107 and INO-5401, which have shown positive Phase 1/2 results. Meanwhile, Advaccine in China will continue developing INO-4800 independently. INOVIO remains focused on advancing its DNA medicines technology for various diseases.